Lonza– tag –
-
WuXi XDC Reports $550.4M H1 Revenue (37% YoY Growth) and Reaffirms $1.2B Investment in ADC Manufacturing Capacity by 2030
Fierce Biotech China Overview WuXi XDC, the ADC-focused subsidiary of WuXi Bio, reported a significant 37% year-over-year revenue increase to RMB 3.7 billion (approximately $550.4 million) in the first half of 2026. The company also reaf... -
Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal
Herbert Smith Freehills Kramer Global Overview The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun P... -
Samsung Biologics Expands to 845,000L Capacity with GSK Facility Acquisition; Lonza, Resilience Announce Major Investments Amidst CDMO Restructuring
DCAT Value Chain Insights USA, South Korea, Switzerland Overview The CDMO industry is undergoing unprecedented restructuring in 2026, driven by major strategic investments and M&A activities by leading players. Samsung Biologics acqu... -
Biologics CDMO Market to Reach $38.29 Billion by 2031, Fill-Finish Emerging as Key Segment
GlobeNewswire Global Overview This article provides an overview of a market research report from GlobeNewswire. The Biologics CDMO market is projected to grow from $27.13 billion in 2026 to $38.29 billion by 2031, exhibiting a CAGR of 7.... -
Point-of-Care Manufacturing Accelerates for Cell and Gene Therapies; Lonza Cocoon Sale Reshapes Industry Landscape
BioPharm International International Overview Point-of-care (PoC) manufacturing for biopharmaceuticals, particularly cell and gene therapies, is gaining momentum, with systems like Lonza's Cocoon and Miltenyi Biotec's CliniMACS Prodigy p... -
Lonza Unveils Rapid Media Prototyping Service (RaMP) to Accelerate Early Biopharmaceutical Development
Lonza Switzerland Overview Lonza launched its Rapid Media Prototyping Service (RaMP), offering biopharmaceutical companies swift access to customized liquid and powder media for accelerated early development. This service provides non-GM... -
Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout
Samsung Biologics South Korea Overview Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide G... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin... -
Cracking the Cost Code: Cellares’ Automated Platform Targets 75% Reduction in CAR-T Manufacturing, Pinpointing Viral Vectors as Key Driver
IntuitionLabs USA Overview A new analysis highlights viral vectors as the primary cost driver in CAR-T cell therapy manufacturing, prompting an urgent need for more efficient production. While existing closed-system platforms offer incre...
